Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Javier De Diego-Adeliño, José Manuel Crespo, Fernando Mora, Adrián Neyra, Pedro Iborra, Luis Gutiérrez-Rojas & Selman F. Salonia. (2022) Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opinion on Drug Safety 21:5, pages 673-690.
Read now
Read now
Dorota Danielak. (2021) Vortioxetine in management of major depressive disorder – a favorable alternative for elderly patients?. Expert Opinion on Pharmacotherapy 22:9, pages 1167-1177.
Read now
Read now
Kokuvi Atsou, Larry Ereshefsky, Mélanie Brignone, Natalya Danchenko, Françoise Diamand, Lisa Mucha, Maëlys Touya, Russell Becker & Clément François. (2021) Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant. Expert Review of Pharmacoeconomics & Outcomes Research 21:1, pages 29-42.
Read now
Read now
Gang Wang, Kun Zhao, Caroline Reynaud-Mougin, Henrik Loft, Hongye Ren, Hanne-Lise F. Eriksen & Anders Ettrup. (2020) Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Current Medical Research and Opinion 36:5, pages 875-882.
Read now
Read now
Erkki Soini, Ossi Riekkinen, Heikki Kröger, Petri Mankinen, Taru Hallinen & Janne P Karjalainen. (2018) Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management. ClinicoEconomics and Outcomes Research 10, pages 279-292.
Read now
Read now
Michael Cronquist Christensen & Vicki Munro. (2018) Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome. Current Medical Research and Opinion 34:4, pages 593-600.
Read now
Read now
Articles from other publishers (9)
Andreea DobrescuAndrea Chapman, Lisa Affengruber, Emma Persad, Ana ToromanovaGernot Wagner, Irma Klerings, Robert EmprechtingerGerald Gartlehner. (2023) Cost-Effectiveness of First- and Second-Step Treatment Strategies for Major Depressive Disorder. Annals of Internal Medicine 176:2, pages 212-216.
Crossref
Crossref
Fang Li, Frederike Jörg, Xinyu Li & Talitha Feenstra. (2022) A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process. PharmacoEconomics 40:11, pages 1015-1032.
Crossref
Crossref
N.N. Petrova & A.A. Mukhin. (2022) Mechanisms of action and clinical effects of vortioxetine. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122:6, pages 84.
Crossref
Crossref
Juliane Andrea Duevel, Lena Hasemann, Luz María Peña-Longobardo, Beatriz Rodríguez-Sánchez, Isaac Aranda-Reneo, Juan Oliva-Moreno, Julio López-Bastida & Wolfgang Greiner. (2020) Considering the societal perspective in economic evaluations: a systematic review in the case of depression. Health Economics Review 10:1.
Crossref
Crossref
Firouzeh Borhannejad, Behnam Shariati, Sina Naderi, Mohammadreza Shalbafan, Amirhosein Mortezaei, Erfan Sahebolzamani, Atefe Saeb, Seyyed Hosein Mortazavi, Leila Kamalzadeh, Ali Aqamolaei, Ahmad Ali Noorbala, Alireza Namazi‐Shabestari & Shahin Akhondzadeh. (2020) Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics 45:4, pages 804-811.
Crossref
Crossref
Felix-Martin Werner & Rafael Coveñas. (2019) Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and Neuropeptides. Current Pharmaceutical Design 25:4, pages 388-395.
Crossref
Crossref
Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno & Eduard Vieta. (2018) Vortioxetine: A new alternative for the treatment of major depressive disorder. Revista de Psiquiatría y Salud Mental (English Edition) 11:1, pages 48-59.
Crossref
Crossref
Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno & Eduard Vieta. (2018) Vortioxetina: una nueva alternativa en el trastorno depresivo mayor. Revista de Psiquiatría y Salud Mental 11:1, pages 48-59.
Crossref
Crossref
Erkki Soini, Jaana Joutseno & Marja-Liisa Sumelahti. (2017) Cost-utility of First-line Disease-modifying Treatments for Relapsing–Remitting Multiple Sclerosis. Clinical Therapeutics 39:3, pages 537-557.e10.
Crossref
Crossref